Pilosof T, Andreev T
Vutr Boles. 1975;14(1):93-9.
Treatment with the preparation "Sanokrizin", applied i. v. has been carried out to 50 patients with rheumatoid polyarthritis--32 seropositive and 18 seronegative forms, being with a duration of the morbid process from one to 17 years. Therapeutic effect was obtained in 78 per cent of the cases, followed up from six months to one year while that therapy proved to be without effect in 22 per cent of the patients or only separate symptoms of the inflammatory process were partially affected. The preparation has a good tolerance and the side-effects, in the absence of controlled auremia, are overcome with discontinuation of the carried out treatment and only to two of the patients corticosteroids were given additionally. With an average dose, per course, of 1751,60 mg effect was also obtained upon single symptoms of the rheumatoid inflammation. The patients, effected at the earliest in the course of the therapeutic process, are with the best and most durable therapeutic effect and that might be used as a prognostic criterion for the favourable effect of the carried out treatment with the preparation "Sanokrizin".
对50例类风湿性多关节炎患者进行了静脉注射“Sanokrizin”制剂的治疗，其中32例为血清阳性型，18例为血清阴性型，病程为1至17年。78%的病例获得了治疗效果，随访时间为6个月至1年，而22%的患者治疗无效或仅炎症过程的个别症状得到部分改善。该制剂耐受性良好，在无控制性金黄色葡萄球菌血症的情况下，停止治疗后副作用即可消除，仅对两名患者额外给予了皮质类固醇。每疗程平均剂量为1751.60毫克时，对类风湿性炎症的个别症状也有效果。在治疗过程中最早起效的患者，治疗效果最佳且最持久，这可作为使用“Sanokrizin”制剂治疗产生良好效果的预后标准。
